Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 30:2022:2402567.
doi: 10.1155/2022/2402567. eCollection 2022.

Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells

Yu Liu  1 , Yan Zhao  2 , Chongxu Han  3 , Chuanli Ren  3
Affiliations

Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells

Yu Liu et al. Comput Math Methods Med. .

Retraction in

Abstract

Objective: To study the expression and prognostic value of CDK6 in stomach cancer and the function of CDK4/6 inhibitor PD-0332991 on the proliferation of stomach cancer cells.

Methods: Immunohistochemistry was used to detect the expression of CDK6 in stomach cancer tissues and adjacent normal tissues and to analyze the effect of CDK6 on clinicopathological parameters of stomach cancer patients. Kaplan-Meier plotter was employed to study the relationship between CDK6 and overall survival in stomach cancer. Western blot and RT-PCR were used to detect protein and gene expression of CDK6 in different cells. The effects of CDK4/6 inhibitor PD-0332991 on apoptosis and aging of stomach cancer cells were detected by flow cytometry and β-galactosidase aging staining assay. The effects of CDK4/6 inhibitor PD-0332991 on the invasion and migration of stomach cancer cells were explored by the wound healing experiment and the Transwell experiment. The supernatant of stomach cancer cells was collected, and the effect of CDK4/6 inhibitor PD-0332991 on tumor markers of stomach cancer cells was detected by biochemical immunoassay.

Results: (1) CDK6 was highly expressed in stomach cancer tissues and cells. (2) Abnormally elevated CDK6 expression results in shorter survival in stomach cancer patients. (3) CDK4/6 inhibitor PD-0332991 could block the proliferation of stomach cancer cells, but not stomach epithelial proliferation. PD-0332991 could inhibit the secretion of pro-GRP by MGC 823. (4) PD-0332991 could advance the development of the apoptosis and senescence of stomach cancer cells and suppressed the invasion and migration of stomach cancer cells.

Conclusion: CDK6 expression is elevated in gastric cancer, and the CDK4/6 inhibitor PD-0332991 can remarkably promote apoptosis and senescence of stomach cancer cells and effectively inhibit the migration and invasion of stomach cancer cells.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Figures

Figure 1
Figure 1
Expression of CDK6 in stomach cancer. (a, b) Expression of CDK6 in stomach cancer tissues. (c) Expression of CDK6 mRNA in stomach cancer cells and stomach epithelial cells. (d, e) Expression of CDK6 protein in stomach cancer cells and stomach epithelial cells. (f) The effect of CDK6 on the overall productivity of stomach cancer patients.
Figure 2
Figure 2
The effect of PD-0332991 on the proliferation of stomach cancer cells. (a–d) The growth curves of the inhibition effects of PD-0332001 on SNU-1, AGS, MKN45, and MKN1, respectively. (e) The effect of PD-0332991 on the secretion of pro-GRP by BGC-823.
Figure 3
Figure 3
Effects of PD-0332991 on senescence, apoptosis, migration, and invasion of stomach cancer cells. (a, b) PD-0332991 promotes stomach cancer cell senescence. (c) PD-0332991 promotes stomach cancer cell apoptosis. (d–g) PD-0332991 inhibits stomach cancer cell invasion and migration.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kamposioras K., Vassilakopoulou M., Anthoney A., et al. Prognostic significance and therapeutic implications of Caveolin-1 in gastrointestinal tract malignancies. Pharmacology & Therapeutics . 2021;(article 108028) doi: 10.1016/j.pharmthera.2021.108028. - DOI - PubMed
    1. Wang D., Cabalag C. S., Clemons N. J., DuBois R. N. Cyclooxygenases and prostaglandins in tumor immunology and microenvironment of gastrointestinal cancer. Gastroenterology . 2021;161(6):1813–1829. doi: 10.1053/j.gastro.2021.09.059. - DOI - PubMed
    1. Joshi S. S., Badgwell B. D. Current treatment and recent progress in gastric cancer. CA: a Cancer Journal for Clinicians . 2021;71(3):264–279. doi: 10.3322/caac.21657. - DOI - PMC - PubMed
    1. Liu C., Huang Y., Cui Y., et al. The immunological role of CDK4/6 and potential mechanism exploration in ovarian cancer. Frontiers in Immunology . 2022;12, article 799171 doi: 10.3389/fimmu.2021.799171. - DOI - PMC - PubMed
    1. Asghar U., Witkiewicz A. K., Turner N. C., Knudsen E. S. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nature Reviews Drug Discovery . 2015;14(2):130–146. doi: 10.1038/nrd4504. - DOI - PMC - PubMed

Publication types

MeSH terms